MedTrace Logo

Understanding Clinician Utilization of Corus CAD (Age/Sex/Gene Expression Score - ASGES) in Clinical Decision Making

NCT02223286 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 552

Last updated 2018-02-22

No results posted yet for this study

Summary

The purpose of this study is to understand the use of Corus CAD also known as Age/Sex/Gene Expression score (ASGES) in the clinical decision making process of patients who underwent the evaluation of chest pain or anginal equivalent symptoms. Specifically, to better understand whether the use of the assay in clinical decision making resulted in changes in noninvasive diagnostic test ordering or diagnostic yield of additional tests ordered and/or invasive angiography.

Conditions

Interventions

DIAGNOSTIC_TEST

Corus CAD

Age/Sex/Gene Expression Score

Sponsors & Collaborators

  • CardioDx

    lead INDUSTRY

Principal Investigators

  • David Hoffman, DO · Northeast Ohio Medical University

  • Lawrence Kline, DP · John C. Lincoln Heart Institute

  • Jaime Burkle, MD · Piedmont Heart Institute

Eligibility

Min Age
21 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-03-31
Primary Completion
2014-06-30
Completion
2014-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02223286 on ClinicalTrials.gov